Novartis AG

Novartis AG is a global pharmaceutical company engaged in the research, development, manufacturing, distribution, and sale of prescription medicines.

The company operates in Switzerland and internationally, with a focus on delivering treatments across several key therapeutic areas.

• Cardiovascular & Metabolic

  • Entresto: For chronic heart failure with reduced ejection fraction (HFrEF)

  • Leqvio: To lower LDL cholesterol (in collaboration with Alnylam)

• Immunology & Inflammatory Diseases

  • Cosentyx: For plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis

  • Xolair: For allergic asthma and nasal polyps

  • Ilaris: For fever syndromes, Still’s disease, and acute gouty arthritis

• Oncology & Hematology

  • Kisqali: CDK4/6 inhibitor for breast cancer

  • Promacta/Revolade: For immune thrombocytopenia (ITP) and severe aplastic anemia (SAA)

  • Tafinlar + Mekinist: Combination therapy for certain cancers

  • Jakavi: For myelofibrosis, polycythemia vera, and graft-versus-host disease (GvHD)

  • Tasigna: For Philadelphia chromosome-positive chronic myeloid leukemia

  • Pluvicto: For metastatic prostate cancer

  • Lutathera, Scemblix, Fabhalta: For various cancer and hematologic conditions

• Neuroscience & Rare Diseases

  • Zolgensma: Gene therapy for spinal muscular atrophy

  • Lucentis: For retinal disorders

  • Sandostatin (SC and LAR): For acromegaly and neuroendocrine tumors

Novartis continues to expand its pipeline and global presence through strategic collaborations, including its agreement with Alnylam Pharmaceuticals to develop and commercialize Leqvio (inclisiran).

Founded in 1996, Novartis AG is headquartered in Basel, Switzerland.